Shibuya Meito, Tamiya Shigeyuki, Kawai Atsushi, Hirai Toshiro, Cragg Mark S, Yoshioka Yasuo
Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
iScience. 2021 Sep 15;24(10):103131. doi: 10.1016/j.isci.2021.103131. eCollection 2021 Oct 22.
Current influenza vaccines do not typically confer cross-protection against antigenically mismatched strains. To develop vaccines conferring broader cross-protection, recent evidence indicates the crucial role of both cross-reactive antibodies and viral-specific CD4 T cells; however, the precise mechanism of cross-protection is unclear. Furthermore, adjuvants that can efficiently induce cross-protective CD4 T cells have not been identified. Here we show that CpG oligodeoxynucleotides combined with aluminum salts work as adjuvants for influenza vaccine and confer strong cross-protection in mice. Both cross-reactive antibodies and viral-specific CD4 T cells contributed to cross-protection synergistically, with each individually ineffective. Furthermore, we found that downregulated expression of Fcγ receptor IIb on alveolar macrophages due to IFN-γ secreted by viral-specific CD4 T cells improves the activity of cross-reactive antibodies. Our findings inform the development of optimal adjuvants for vaccines and how influenza vaccines confer broader cross-protection.
目前的流感疫苗通常不能对抗原不匹配的毒株提供交叉保护。为了开发具有更广泛交叉保护作用的疫苗,最近的证据表明交叉反应性抗体和病毒特异性CD4 T细胞都起着关键作用;然而,交叉保护的确切机制尚不清楚。此外,尚未鉴定出能有效诱导交叉保护性CD4 T细胞的佐剂。在此,我们表明,与铝盐结合的CpG寡脱氧核苷酸可作为流感疫苗的佐剂,并在小鼠中提供强大的交叉保护。交叉反应性抗体和病毒特异性CD4 T细胞协同促成交叉保护,单独作用时均无效。此外,我们发现,病毒特异性CD4 T细胞分泌的IFN-γ导致肺泡巨噬细胞上Fcγ受体IIb的表达下调,从而提高了交叉反应性抗体的活性。我们的研究结果为开发最佳疫苗佐剂以及流感疫苗如何提供更广泛的交叉保护提供了依据。